DrugPatentWatch Database Preview
Drugs in Development Information for Reparixin
» See Plans and Pricing
What is the development status for investigational drug Reparixin?
Reparixin is an investigational drug.
There have been 9 clinical trials for Reparixin.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2012.
The most common disease conditions in clinical trials are Breast Neoplasms, Diabetes Mellitus, Type 1, and Diabetes Mellitus. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A, PRA Health Sciences, and [disabled in preview].
There are eighty-two US patents protecting this investigational drug and seven hundred and seventy-four international patents.
Summary for Reparixin
| US Patents | 82 |
| International Patents | 774 |
| US Patent Applications | 213 |
| WIPO Patent Applications | 140 |
| Japanese Patent Applications | 62 |
| Clinical Trial Progress | Phase 2 (2012-10-01) |
| Vendors | 32 |
Recent Clinical Trials for Reparixin
| Title | Sponsor | Phase |
|---|---|---|
| Reparixin in COVID-19 Pneumonia - Multicentre Study on the Efficacy and Safety | Dompé Farmaceutici S.p.A | Phase 2/Phase 3 |
| A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer | PRA Health Sciences | Phase 2 |
| A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer | Dompé Farmaceutici S.p.A | Phase 2 |
Clinical Trial Summary for Reparixin
Top disease conditions for Reparixin
Top clinical trial sponsors for Reparixin
US Patents for Reparixin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Reparixin | Start Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| Reparixin | Start Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| Reparixin | Start Trial | Combination therapy | DIMERIX BIOSCIENCE PTY LTD. (Victoria, AU) | Start Trial |
| Reparixin | Start Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| Reparixin | Start Trial | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders | OTONOMY, INC. (San Diego, CA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) | Start Trial |
| Reparixin | Start Trial | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| Reparixin | Start Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Reparixin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Reparixin | Canada | CA2961033 | 2034-09-11 | Start Trial |
| Reparixin | European Patent Office | EP3192791 | 2034-09-11 | Start Trial |
| Reparixin | Japan | JPWO2016039408 | 2034-09-11 | Start Trial |
| Reparixin | World Intellectual Property Organization (WIPO) | WO2016039408 | 2034-09-11 | Start Trial |
| Reparixin | Argentina | AR098909 | 2033-07-03 | Start Trial |
| Reparixin | European Patent Office | EP3018126 | 2033-07-03 | Start Trial |
| Reparixin | Japan | JP6427491 | 2033-07-03 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
